Last reviewed · How we verify

Dulaglutide,QW

CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. · Phase 2 active Small molecule Under review

Dulaglutide,QW is a GLP-1 receptor agonist Small molecule drug developed by CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.. It is currently in Phase 2 development for Type 2 diabetes. Also known as: Dulaglutide,subcutaneous injection,QW.

GLP-1 receptor agonist

Dulaglutide, QW is a glucagon-like peptide 1 receptor agonist used to treat Type 2 Diabetes. It belongs to the drug class of AGONIST and acts on the protein target Glucagon-like peptide 1 receptor.

Likelihood of approval
15.3% vs 15.3% industry baseline
If approved by FDA: likely 2031–2034
Steps remaining: Phase 3 → NDA/BLA submission
Confidence: Medium
Why this estimate
  • Baseline phase 2 → approval rate +15.3pp
    Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
Predicted approval windows by jurisdiction (conditional on FDA approval)
Regulator Country Likely year Lag vs FDA
FDA US 2031–2034 —
EMA EU 2032–2035 +0.7 yr
MHRA GB 2032–2035 +0.7 yr
Health Canada CA 2032–2036 +0.9 yr
TGA AU 2032–2036 +1.2 yr
PMDA JP 2032–2036 +1.5 yr
NMPA CN 2033–2037 +2.3 yr
MFDS KR 2032–2036 +1.4 yr
CDSCO IN 2032–2037 +1.8 yr
ANVISA BR 2033–2037 +2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic nameDulaglutide,QW
Also known asDulaglutide,subcutaneous injection,QW
SponsorCSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
Drug classGLP-1 receptor agonist
TargetGLP-1R
ModalitySmall molecule
Therapeutic areaDiabetes
PhasePhase 2

Mechanism of action

Dulaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that mimics the action of the incretin hormone GLP-1 to enhance glucose-dependent insulin secretion, suppress inappropriate glucagon secretion, and slow gastric emptying.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Dulaglutide,QW

What is Dulaglutide,QW?

Dulaglutide,QW is a GLP-1 receptor agonist drug developed by CSPC Baike (Shandong) Biopharmaceutical Co., Ltd., indicated for Type 2 diabetes.

How does Dulaglutide,QW work?

GLP-1 receptor agonist

What is Dulaglutide,QW used for?

Dulaglutide,QW is indicated for Type 2 diabetes.

Who makes Dulaglutide,QW?

Dulaglutide,QW is developed by CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. (see full CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. pipeline at /company/cspc-baike-shandong-biopharmaceutical-co-ltd).

Is Dulaglutide,QW also known as anything else?

Dulaglutide,QW is also known as Dulaglutide,subcutaneous injection,QW.

What drug class is Dulaglutide,QW in?

Dulaglutide,QW belongs to the GLP-1 receptor agonist class. See all GLP-1 receptor agonist drugs at /class/glp-1-receptor-agonist.

What development phase is Dulaglutide,QW in?

Dulaglutide,QW is in Phase 2.

What are the side effects of Dulaglutide,QW?

Common side effects of Dulaglutide,QW include Nausea, Vomiting, Diarrhea.

What does Dulaglutide,QW target?

Dulaglutide,QW targets GLP-1R and is a GLP-1 receptor agonist.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing